Aridis Pharmaceuticals Analyst Ratings
Aridis Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | 713.01% | HC Wainwright & Co. | $19 → $10 | Maintains | Buy |
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 1444.72% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 794.31% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 1363.41% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 469.11% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 09/10/2018 | 3152.03% | Northcoast Research | → $40 | Initiates Coverage On | → Outperform |
| 09/10/2018 | 1769.92% | Laidlaw & Co. | → $23 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1932.52% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 01/26/2023 | 713.01% | HC Wainwright & Co. | 19 美元 → 10 美元 | 维护 | 买 |
| 08/16/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 07/20/2021 | 1444.72% | HC Wainwright & Co. | 11 美元 → 19 美元 | 维护 | 买 |
| 05/15/2020 | 794.31% | HC Wainwright & Co. | 7 美元 → 11 美元 | 重申 | → 购买 |
| 02/19/2020 | 1363.41% | 罗斯资本 | → 18 美元 | 开启覆盖范围 | → 购买 |
| 2019 年 12 月 30 日 | 469.11% | HC Wainwright & Co. | → 7 美元 | 开启覆盖范围 | → 购买 |
| 09/10/2018 | 3152.03% | 北海岸研究 | → 40 美元 | 开启覆盖范围 | → 跑赢大盘 |
| 09/10/2018 | 1769.92% | Laidlaw & Co. | → 23 美元 | 开启覆盖范围 | → 购买 |
| 09/10/2018 | 1932.52% | 坎托·菲茨杰拉德 | → 25 美元 | 开启覆盖范围 | → 超重 |
What is the target price for Aridis Pharmaceuticals (ARDS)?
Aridis Pharmicals（ARDS）的目标价格是多少？
The latest price target for Aridis Pharmaceuticals (NASDAQ: ARDS) was reported by HC Wainwright & Co. on January 26, 2023. The analyst firm set a price target for $10.00 expecting ARDS to rise to within 12 months (a possible 713.01% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年1月26日公布了Aridis Pharmicals（纳斯达克股票代码：ARDS）的最新目标股价。这家分析公司将目标价设定为10.00美元，预计ARDS将在12个月内升至713.01％（可能上涨713.01％）。去年，有两家分析公司公布了评级。
What is the most recent analyst rating for Aridis Pharmaceuticals (ARDS)?
Aridis Pharmicals（ARDS）的最新分析师评级是多少？
The latest analyst rating for Aridis Pharmaceuticals (NASDAQ: ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals maintained their buy rating.
Aridis Pharmicals（纳斯达克股票代码：ARDS）的最新分析师评级由HC Wainwright & Co. 提供，Aridis Pharmicals维持了买入评级。
When is the next analyst rating going to be posted or updated for Aridis Pharmaceuticals (ARDS)?
Aridis Pharmicals（ARDS）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与Aridis Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。Aridis Pharmicals的最新评级是在2023年1月26日公布的，因此你应该预计下一个评级将在2024年1月26日左右公布。
Is the Analyst Rating Aridis Pharmaceuticals (ARDS) correct?
分析师对阿里迪斯制药（ARDS）的评级是否正确？
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a maintained with a price target of $19.00 to $10.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $1.23, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Aridis Pharmicals（ARDS）评级保持不变，目标价为19.00美元至10.00美元。Aridis Pharmicals（ARDS）目前的交易价格为1.23美元，超出了分析师的预期区间。